X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13107) 13107
Publication (2063) 2063
Book Chapter (291) 291
Book Review (217) 217
Dissertation (58) 58
Conference Proceeding (31) 31
Government Document (25) 25
Book / eBook (9) 9
Reference (4) 4
Data Set (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
receptor tyrosine kinase (7704) 7704
humans (7322) 7322
animals (6214) 6214
index medicus (4991) 4991
receptor tyrosine kinases (3140) 3140
mice (2852) 2852
oncology (2803) 2803
biochemistry & molecular biology (2785) 2785
cell biology (2637) 2637
signal transduction (2521) 2521
female (2168) 2168
expression (1856) 1856
cancer (1782) 1782
male (1776) 1776
phosphorylation (1641) 1641
mutation (1309) 1309
angiogenesis (1243) 1243
activation (1182) 1182
receptor protein-tyrosine kinases - metabolism (1174) 1174
tyrosine (1171) 1171
cell line, tumor (1128) 1128
research (1088) 1088
receptor protein-tyrosine kinases - genetics (1048) 1048
article (1033) 1033
proteins (986) 986
molecular sequence data (954) 954
developmental biology (907) 907
kinases (886) 886
endothelial growth-factor (869) 869
middle aged (836) 836
amino acid sequence (834) 834
in-vivo (831) 831
rats (829) 829
ligands (816) 816
adult (810) 810
analysis (797) 797
apoptosis (794) 794
gene expression (773) 773
genetics & heredity (767) 767
cells (761) 761
genetic aspects (752) 752
cell line (747) 747
cells, cultured (742) 742
pharmacology & pharmacy (741) 741
signal transduction - physiology (735) 735
protein (717) 717
immunohistochemistry (714) 714
growth (691) 691
neurosciences (683) 683
aged (677) 677
metastasis (657) 657
physiological aspects (648) 648
hematology (643) 643
gene (636) 636
growth-factor receptor (612) 612
growth-factor (607) 607
antineoplastic agents - pharmacology (599) 599
tumors (593) 593
protein binding (580) 580
cell proliferation (578) 578
signal transduction - drug effects (561) 561
in-vitro (549) 549
antineoplastic agents - therapeutic use (544) 544
signal-transduction (533) 533
proto-oncogene proteins - metabolism (526) 526
breast-cancer (515) 515
protein kinase inhibitors - pharmacology (513) 513
health aspects (504) 504
base sequence (501) 501
models, biological (494) 494
c-met (492) 492
gene-expression (491) 491
prognosis (487) 487
biology (484) 484
proto-oncogene proteins - genetics (482) 482
chemotherapy (475) 475
medicine, research & experimental (473) 473
epidermal growth factor (471) 471
care and treatment (469) 469
vascular endothelial growth factor (462) 462
receptor, epidermal growth factor - metabolism (455) 455
gene expression regulation, neoplastic (451) 451
multidisciplinary sciences (450) 450
survival (448) 448
identification (440) 440
gene expression regulation, developmental (438) 438
blotting, western (437) 437
research article (437) 437
biophysics (430) 430
lung cancer (429) 429
transfection (427) 427
lung neoplasms - drug therapy (419) 419
tumor cells, cultured (417) 417
cell lung-cancer (415) 415
cell proliferation - drug effects (415) 415
pathology (415) 415
cell differentiation (413) 413
mutations (408) 408
tyrosine kinase (404) 404
protein structure, tertiary (395) 395
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12540) 12540
Chinese (369) 369
Japanese (347) 347
German (49) 49
French (35) 35
Korean (11) 11
Spanish (11) 11
Polish (7) 7
Hungarian (5) 5
Russian (4) 4
Czech (2) 2
Turkish (2) 2
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biochemical Journal, ISSN 0264-6021, 12/2007, Volume 408, Issue 3, pp. 297 - 315
The specificities of 65 compounds reported to be relatively specific inhibitors of protein kinases have been profiled against a panel of 70-80 protein kinases.... 
Drug discovery | Kinase profiling | Protein kinase | Anti-cancer drugs | Inhibitor specificity | RHO-ASSOCIATED KINASE | TUMOR PROGRESSION | FAMILY-MEMBERS | BIOCHEMISTRY & MOLECULAR BIOLOGY | CELL-PROLIFERATION | protein kinase | P38 MAP KINASE | CYCLIN-DEPENDENT KINASES | RECEPTOR TYROSINE KINASES | drug discovery | kinase profiling | SB 203580 | anti-cancer drugs | ISOFORMS IN-VITRO | P90 RSK | inhibitor specificity | Amino Acid Sequence | Cell Line | Phosphorylation | Recombinant Proteins - antagonists & inhibitors | Animals | Mitogen-Activated Protein Kinases - antagonists & inhibitors | Humans | Drug Design | Protein Kinase Inhibitors - pharmacology | Enzyme Activation | Mitogen-Activated Protein Kinases - metabolism | Spodoptera | Yes1, Yamaguchi sarcoma viral oncogene homologue 1 | CSK, C-terminal Src kinase | Lck, lymphocyte cell-specific protein-tyrosine kinase | EGF, epidermal growth factor | FGF-R, fibroblast-growth-factor receptor | PAK, p21-activated protein kinase | PDK, 3-phosphoinositide-dependent protein kinase | PI3K, phosphatidylinositol (phosphoinositide) 3-kinase | NEK, NIMA (never in mitosis in Aspergillus nidulans)-related kinase | RSK, p90 ribosomal S6 kinase | HEK-293 cells, human embryonic kidney-293 cells | VEGF, vascular endothelial growth factor (vasoendothelial growth factor) | EF2K, elongation-factor-2 kinase | CK, casein kinase | PTEN, phosphatase and tensin homologue deleted on chromosome 10 | ERK, extracellular-signal-regulated kinase | ATM, ataxia telangiectasia mutated | SRPK, serine-arginine protein kinase | IL-1, interleukin 1 | MNK, MAPK-integrating protein kinase | ROCK, Rho-dependent protein kinase | CaMKK, CaMK kinase | GST, glutathione transferase | MKK1, MAPK kinase-1 (also called MEK1, MAPK or ERK kinase 1) | GAK, cyclin G-associated kinase | FMK, fluoromethylketone | MST, mammalian homologue Ste20-like kinase | PKA, cAMP-dependent protein kinase | FKBP, FK506-binding protein | PPAR, peroxisome-proliferator-activated receptor | IKK, inhibitory κB kinase | PH, pleckstrin homology | MBP, myelin basic protein | AICAR, aminoimidazole-4-carboxamide-1-β-D-ribofuranoside | MAPKAP-K, MAPK-activated protein kinase | Sf21, Spodoptera frugiperda (fall armyworm) 21 | MARK, microtubule-affinity-regulating kinase | PIM, provirus integration site for Moloney murine leukaemia virus | LPS, lipopolysaccharide | MSK, mitogen- and stress-activated protein kinase | MAPK, mitogen-activated protein kinase | MELK, maternal embryonic leucine-zipper kinase | His6, hexahistidine | CAK, cyclin-dependent kinase-activating kinase | Eph-A2, Ephrin A2 receptor | PLK, polo-like kinase | ATF2, activating transcription factor 2 | PKD, protein kinase D | Src, sarcoma kinase | AMPK, AMP-activated protein kinase | MMS, methyl methanesulfonate | CHK, checkpoint kinase | JNK, c-Jun N-terminal kinase | TORC1, mTOR (mammalian target of rapamycin)–raptor (regulatory associated protein of mTOR) complex | BRSK, brain-specific kinase | RIP2, receptor-interacting protein 2 | IGF-1, insulin-like growth factor-1 | S6K1, S6 kinase 1 | DYRK, dual-specificity tyrosine-phosphorylated and -regulated kinase | HIPK, homeodomain-interacting protein kinase | ZMP, aminoimidazole-4-carboxamide-1-β-D-ribofuranoside monophosphate | PRAK, p38-regulated activated kinase | PKC, protein kinase C | Src-I1, Src inhibitor 1 | TANK, TRAF (tumour-necrosis-factor-receptor-associated factor)-family-member-associated nuclear factor κB activator | NFAT, nuclear factor for activated T-cells | PHK, phosphorylase kinase | GSK3, glycogen synthase kinase 3 | PKB, protein kinase B (also called Akt) | CaMK, calmodulin-dependent kinase | CDK, cyclin-dependent protein kinase | NDRG, N-myc downstream-regulated gene | SmMLCK, smooth-muscle myosin light-chain kinase | TBK1, TANK-binding kinase 1 | PRK, protein kinase C-related kinase | SGK, serum- and glucocorticoid-induced kinase
Journal Article
Science, ISSN 0036-8075, 02/2017, Volume 355, Issue 6327, pp. 836 - 842
Journal Article
Biochemical Journal, ISSN 0264-6021, 12/2005, Volume 392, Issue 2, pp. 249 - 261
The MAPK (mitogen-activated protein kinase) pathway is one of the most important and intensively studied signalling pathways. It is at the heart of a... 
Receptor tyrosine kinase | Signalling network | Systems biology | Extracellular-signal-regulated kinase (ERK) | Computational modelling | Mitogen-activated protein kinase (MAPK) | systems biology | EARLY GENE-PRODUCTS | PROTEIN-KINASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | mitogen-activated protein kinase (MAPK) | BIOCHEMICAL NETWORKS | QUANTITATIVE-ANALYSIS | ERK ACTIVATION | extracellular-signal-regulated kinase (ERK) | GROWTH-FACTOR RECEPTOR | COMPLEX-FORMATION | signalling network | DUAL PHOSPHORYLATION | computational modelling | receptor tyrosine kinase | SIGNAL-REGULATED KINASE | Mitogen-Activated Protein Kinase Kinases - metabolism | Animals | Receptor Protein-Tyrosine Kinases - metabolism | Models, Biological | Computer Simulation | MAP Kinase Signaling System | MEK, MAPK | ODE, ordinary differential equation | MAPKK | MP1, MEK partner 1 | NGF, nerve growth factor | MKP, MAPK phosphatase | Review | MCA, Metabolic Control Analysis | ERK kinase | ERK, extracellular-signal-regulated kinase | PKA, cAMP-activated protein kinase | Shc, Src homology and collagen homology | STAT5, signal transduction and activator of transcription 5 | RSK, ribosomal S6 kinase | FBA, Flux Balance Analysis | SOS, son of sevenless | CD domain, common docking domain | MKKK, MAPKK kinase | PLCγ, phospholipase Cγ | EGF(R), epidermal growth factor (receptor) | FGF, fibroblast growth factor | MKK, MAPK kinase | SBML, Systems Biology Markup Language | JIP, JNK (c-Jun N-terminal kinase)-interacting protein | PDE4, phosphodiesterase 4 | KSR, kinase suppressor of Ras | MAPKKK | Grb2, growth-factor-receptor-bound protein 2 | RTK, receptor tyrosine kinase | GAP, GTPase-activating protein | PDGF, platelet-derived growth factor | MAPK, mitogen-activated protein kinase
Journal Article
Biochemical Journal, ISSN 0264-6021, 06/2009, Volume 420, Issue 3, pp. 345 - 361
RTKs (receptor tyrosine kinases) play important roles in cellular proliferation and different liation. In addition, RTKs reveal oncogenic potential when their... 
Extracellular-signal-regulated kinase (ERK) | Pleiotrophin | Anaplastic large cell lymphoma (ALCL) | Neuroblastoma | Non-small cell lung cancer (NSLCL) | Midkine | Anaplastic lymphoma kinase (ALK) | Inflammatory myofibroblastic tumour (IMT) | inflammatory myofibroblastic tumour (IMT) | GROWTH-FACTOR PLEIOTROPHIN | non-small cell lung cancer (NSLCL) | BIOCHEMISTRY & MOLECULAR BIOLOGY | anaplastic lymphoma kinase (ALK) | EML4-ALK FUSION GENE | neuroblastoma | LARGE-CELL LYMPHOMA | HUMAN BREAST-CANCER | extracellular-signal-regulated kinase (ERK) | TFG-ALK TRANSLOCATIONS | pleiotrophin | NEUROTROPHIC FACTOR HBNF | INFLAMMATORY MYOFIBROBLASTIC TUMOR | NON-HODGKINS-LYMPHOMA | midkine | anaplastic large cell lymphoma (ALCL) | GASTROINTESTINAL STROMAL TUMORS | RECEPTOR TYROSINE KINASE | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Oncogene Proteins, Fusion - metabolism | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Protein-Tyrosine Kinases - metabolism | Humans | Lung Neoplasms - metabolism | Neuroblastoma - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Lung Neoplasms - pathology | Nuclear Proteins - metabolism | Receptor Protein-Tyrosine Kinases | Protein-Tyrosine Kinases - genetics | Models, Biological | Oncogene Proteins, Fusion - genetics | Lymphoma, Large-Cell, Anaplastic - pathology | Neuroblastoma - metabolism | Nuclear Proteins - genetics | Lymphoma, Large-Cell, Anaplastic - metabolism | Neuroblastoma - pathology | Lymphoma, Large-Cell, Anaplastic - genetics | ALK, anaplastic lymphoma kinase | LTK, leucocyte tyrosine kinase | MUC-1, mucin-1 | IRS-1, IR substrate-1 | PTN, pleiotrophin | TGFβ, transforming growth factor β | ERK, extracellular-signal-regulated kinase | PKB, protein kinase B | Shc, Src homology and collagen homology | TPM, tropomyosin | IMP cyclohydrolase | MK, midkine | MYH9, non-muscle myosin heavy chain | MAM, meprin, A5 protein and receptor protein tyrosine phosphatase mu | NPM, nucleophosmin | mTOR, mammalian target of rapamycin | NIPA, nuclear interacting partner of ALK | RPTP, receptor protein tyrosine phosphatase | DLBCL, diffuse large B-cell lymphoma | FOXO3a, forkhead box O 3a | NF-κB, nuclear factor κB | Shp1, SH2 domain-containing phosphatase 1 | RANBP2, Ran-binding protein 2 | ALCL, anaplastic large cell lymphoma | Dpp, decapentaplegic | FRS2, fibroblast growth factor receptor substrate 2 | LDLa, low-density lipoprotein class A | EGFR, epidermal growth factor receptor | SEC31L1, SEC31 homologue A | GIST, gastrointestinal stromal tumour | RTK, receptor tyrosine kinase | SH2, Src homology 2 | TFG, TRK-fused gene | ATIC, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase | CLTC, clathrin heavy chain | MAPK, mitogen-activated protein kinase | Hen-1, hesitation-1 | MEK, MAPK | PI3K, phosphoinositide 3-kinase | HEK, human embryonic kidney | SCD-2, suppressor of constitutive dauer 2 | Review | EBPβ, CCAAT | CARS, cysteinyl-tRNA synthetase | JNK, c-Jun N-terminal kinase | ERK kinase | Grb2, growthfactor-receptor-bound protein 2 | SCC, squamous cell carcinoma | EML4, echinoderm microtubule-associated protein like 4 | SHH, sonic hedghog | BCR-Abl, breakpoint cluster region-Abl | IR, insulin receptor | ALO17, ALK lymphoma oligomerization partner on chromosome 17 | enhancer-binding protein β | PLCγ, phospholipase Cγ | NSCLC, non-small cell lung cancer | UCN-01, unco-ordinated 1 | Cdc42, cell division cycle 42 | STAT, signal transducer and activator of transcription | DRG, dorsal root ganglia | MSN, moesin | dALK, Drosophila ALK | IL-3, interleukin-3 | CNS, central nervous system | JAK, Janus kinase | CML, chronic myeloid leukaemia | Jeb, jelly belly | IMT, inflammatory myofibroblastic tumour | Medical and Health Sciences | Medicin och hälsovetenskap | MEDICIN | MEDICINE
Journal Article
Biochemical Journal, ISSN 0264-6021, 12/2012, Volume 448, Issue 2, pp. 213 - 220
To investigate the range of autoinhibitory mechanisms used by TKDs (tyrosine kinase domains) from the insulin receptor family of RTKs (receptor tyrosine... 
X-ray crystallography | Insulin receptor kinase | Autoinhibition | Receptor tyrosine kinase (RTK) | Receptor tyrosine kinase-like orphan receptor 2 (Ror2) | Tropomyosin receptor kinase A (TrkA) | ALK | ACTIVATION | CRYSTAL-STRUCTURE | TYROSINE KINASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | CATALYTIC DOMAIN | autoinhibition | receptor tyrosine kinase-like orphan receptor 2 (Ror2) | CANCER | ANAPLASTIC LYMPHOMA KINASE | insulin receptor kinase | receptor tyrosine kinase (RTK) | MUTATIONS | INHIBITOR | tropomyosin receptor kinase A (TrkA) | EGF RECEPTOR | Neoplasms - metabolism | Humans | Receptor, trkA - antagonists & inhibitors | Crystallography, X-Ray | Antigens, CD - genetics | Antigens, CD - metabolism | Neoplasms - genetics | Receptor, Insulin - genetics | Protein Structure, Quaternary | Antigens, CD - chemistry | Recombinant Proteins - metabolism | Amino Acid Sequence | Catalytic Domain | Recombinant Proteins - antagonists & inhibitors | Receptor Tyrosine Kinase-like Orphan Receptors - metabolism | Models, Molecular | Recombinant Proteins - chemistry | Recombinant Proteins - genetics | Receptor, Insulin - antagonists & inhibitors | Amino Acid Motifs | Receptor Tyrosine Kinase-like Orphan Receptors - antagonists & inhibitors | Receptor Tyrosine Kinase-like Orphan Receptors - chemistry | Receptor, trkA - metabolism | Receptor, Insulin - chemistry | Receptor, trkA - chemistry | Receptor, trkA - genetics | Receptor Tyrosine Kinase-like Orphan Receptors - genetics | Receptor, Insulin - metabolism | Mutation | Enzyme Activation - genetics | In Vitro Techniques | ALK, anaplastic lymphoma kinase | FGFR, fibroblast growth factor receptor | Trk, tropomyosin receptor kinase | C-lobe, C-terminal lobe | EGFR, epidermal growth factor receptor | TKD, tyrosine kinase domain | DTT, dithiothreitol | NSCLC, non-small-cell lung cancer | TCEP, tris-(2-carboxyethyl)phosphine | COSMIC, Catalogue Of Somatic Mutations In Cancer | Ni-NTA, Ni2+-nitrilotriacetate | N-lobe, N-terminal lobe | RTK, receptor tyrosine kinase | CDK, cyclin-dependent kinase | IGF1R, insulin-like growth factor 1 receptor | MuSK, muscle-specific kinase | IRK, insulin receptor kinase | Ror, receptor tyrosine kinase-like orphan receptor
Journal Article
International Journal of Oncology, ISSN 1019-6439, 12/2014, Volume 45, Issue 6, pp. 2267 - 2277
Leiomyosarcomas remain challenging tumors to manage and novel therapy strategies besides radiation and conventional chemotherapy are needed. Targeting... 
leiomyosarcoma | tumor | angiogenesis | VEGF | receptor tyrosine kinase | PTK787/ZK222584 | VEGF receptor | small molecule inhibitor | Angiogenesis | Leiomyosarcoma | Receptor tyrosine kinase | Tumor | Small molecule inhibitor | FACTOR VEGF | MIGRATION | PHASE-III | METASTATIC COLORECTAL ADENOCARCINOMA | CANCER | ANTIANGIOGENIC THERAPY | HEPATOCELLULAR-CARCINOMA | ONCOLOGY | ENDOTHELIAL GROWTH-FACTOR | Human Umbilical Vein Endothelial Cells | Vascular Endothelial Growth Factor A - biosynthesis | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Vascular Endothelial Growth Factor Receptor-3 - biosynthesis | Humans | Proto-Oncogene Proteins c-sis - administration & dosage | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Angiogenesis Inhibitors - administration & dosage | Leiomyosarcoma - genetics | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Vascular Endothelial Growth Factor Receptor-2 - biosynthesis | Gene Expression Regulation, Neoplastic - drug effects | Vascular Endothelial Growth Factor A - administration & dosage | Proto-Oncogene Proteins c-sis - biosynthesis | Phthalazines - administration & dosage | Pyridines - administration & dosage | Leiomyosarcoma - pathology | Vascular Endothelial Growth Factor Receptor-1 - biosynthesis | Cell Movement - drug effects | Protein Kinase Inhibitors - administration & dosage | Receptor Protein-Tyrosine Kinases - genetics | Signal Transduction - drug effects | Neovascularization, Pathologic - drug therapy | Cell Line, Tumor | Leiomyosarcoma - drug therapy | Neovascularization, Pathologic - genetics | Vascular Endothelial Growth Factor Receptor-3 - antagonists & inhibitors | Physiological aspects | Research | Angiogenesis inhibitors | Drug therapy | Vascular endothelial growth factor | Health aspects | Biotechnology | Laboratories | Cloning | Clinical trials | Metastasis | Kinases | Cancer therapies | Cell adhesion & migration | Studies | Cell growth | Chemotherapy | Medical prognosis | Ligands | Growth factors | Veins & arteries | Apoptosis
Journal Article
by Pek, M and Yatim, S.M.J.M and Chen, Y and Li, J and Gong, M and Jiang, X and Zhang, F and Zheng, J and Wu, X and Yu, Q
Oncogene, ISSN 0950-9232, 08/2017, Volume 36, Issue 35, pp. 4975 - 4986
Therapeutic strategies against KRAS mutant colorectal cancers are developed using cell line models, which do not accurately represent the transcriptome driven... 
BIOCHEMISTRY & MOLECULAR BIOLOGY | PANCREATIC-CANCER | DNA-DAMAGE | TRANSCRIPTION | SYNTHETIC LETHAL INTERACTION | PROLIFERATION | FOXM1 | SUPPRESSION | CELL BIOLOGY | RECEPTOR TYROSINE KINASES | MUTATION STATUS | ONCOLOGY | GENETICS & HEREDITY | CELL-CYCLE | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Diphenylamine - pharmacology | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Cyclin-Dependent Kinase 4 - genetics | Humans | Gene Expression Profiling | Molecular Targeted Therapy | Diphenylamine - analogs & derivatives | Colorectal Neoplasms - drug therapy | Female | Benzamides - pharmacology | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | MAP Kinase Kinase Kinases - antagonists & inhibitors | Proto-Oncogene Proteins p21(ras) - metabolism | Colorectal Neoplasms - enzymology | MAP Kinase Kinase Kinases - genetics | HCT116 Cells | Cyclin-Dependent Kinase 6 - genetics | Cyclin-Dependent Kinase 6 - metabolism | MAP Kinase Kinase Kinases - metabolism | Random Allocation | Cyclin-Dependent Kinase 4 - metabolism | Mice, SCID | Piperazines - pharmacology | HT29 Cells | Xenograft Model Antitumor Assays | Animals | Cell Line, Tumor | Mice, Inbred NOD | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Care and treatment | Research | Gene mutations | Gene expression | Colorectal cancer | Cell cycle | Cell culture | Toxicity | Epithelial cells | Mitosis | Colorectal carcinoma | Cancer therapies | Cyclin-dependent kinase 4 | K-Ras protein | Metastases | Xenografts | Mutation | Colon | Tumors | Index Medicus
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 09/2011, Volume 54, Issue 18, pp. 6342 - 6363
Journal Article
Seminars in Cancer Biology, ISSN 1044-579X, 06/2018, Volume 50, pp. 77 - 89
The FOXO3 and FOXM1 forkhead box transcription factors, functioning downstream of the essential PI3K-Akt, Ras-ERK and JNK/p38MAPK signalling cascades, are... 
TO-MESENCHYMAL TRANSITION | IN-VITRO | ACTIVATED PROTEIN-KINASE | STEM-LIKE CELLS | ONCOLOGY | DNA-DAMAGE RESPONSE | ESTROGEN-RECEPTOR-ALPHA | JUN NH2-TERMINAL KINASE | FOXO TRANSCRIPTION FACTORS | FORKHEAD BOX M1 | NEGATIVE BREAST-CANCER | DNA Repair - drug effects | Humans | Gene Expression Regulation, Neoplastic | Antineoplastic Agents - therapeutic use | Neoplasms - drug therapy | Cell Self Renewal - genetics | Forkhead Box Protein O3 - genetics | Drug Resistance, Neoplasm - genetics | Neoplasms - genetics | Forkhead Box Protein M1 - genetics | Cell Proliferation - drug effects | Neoplasms - pathology | Drug Resistance, Neoplasm - drug effects | AURKA, aurora kinase A | Fox, forkhead box | Bim, B-cell lymphoma 2 interacting mediator | EGF, epidermal growth factor | JNK | BRIP1, BRCA1-interacting protein-terminal helicase 1 | GICs, glioma-initiating cells | MCL, mantle cell lymphoma | PKB, protein kinase B | SCs, stem cells | LEF, T-cell factor | Skp2, S-phase kinase-associated protein 2 | SSBs, single-strand breaks | mTOR, mammalian target of rapamycin | NBS1, Nijmegen breakage syndrome 1 | stress activated protein kinase | MEK, mitogen-activated protein kinase kinase | PIP3, phosphatidylinositol- 3,4,5-trisphosphate | BER, base excision repair | lymphoid enhancer factor | VEGF, vascular endothelial growth factor | AML, acute myeloid leukaemia | ER+ve, estreogen receptor positive | EXO1, exonuclease 1 | EGFR, epidermal growth factor receptor | MDR1, multidrug resistance protein 1 | ChIP-seq, chromatin immunoprecipitation with massively parallel DNA sequencing | ABCB1, ATP-binding cassette sub-family B member 1 | TCF | SOD-2, superoxide dismutase | TKIs, tyrosine kinase inhibitors | PDK, phosphoinositide-dependent kinase | IFNɣ, interferon-ɣ | BRCA2, breast cancer-associated gene 2 | DDR, DNA damage response | Cks1, cyclin-dependent kinases regulatory subunit 1 | ESR1, estrogen receptor alpha gene | NHEJ, non-homologous end joining | XRCC1, X-ray cross-complementing group 1 | OTUB1, OUT domain-containing ubiquitin aldehyde-binding protein 1 | IGF, insulin growth factor | TRAIL, tumour necrosis factor-related apoptosis inducing ligand | ER, estrogen receptor | MRN, MER11-RAD50-NBS1 | BRCA1, breast cancer susceptibility gene product 1 | FasL, fas ligand | RTKs, receptor tyrosine kinases | Sox1, sex determining region Y box 2 | GADD45, DNA damage-inducible protein 45 | MMR, mismatch repair | PI3K, phosphatidylinositol 3-kinase | ROS, reactive oxygen species | NAMPT, nicotinamide-phosphribosyltransferase | miRs, Micro-RNAs | FHRE, forkhead response element | ATM, Ataxia-telangiectasia mutated | NER, nucleotide excision repair | ERK, extracellular signal-regulated kinase | HR, homologous recombination | AMPK, adenosine monophosphate-activated protein kinase | DSBs, double strands breaks | PA, Psammaplysene A | CML, chronic myeloid leukaemia | HCC, hepatocellular carcinoma | Mst1, macrophage stimulating 1 | Rb2, retinoblastoma-related p130 | SAPK, c-Jun N-terminal kinase | CSCs, cancer stem cells
Journal Article
Nature Reviews Drug Discovery, ISSN 1474-1776, 04/2018, Volume 17, Issue 5, pp. 353 - 376
Receptor tyrosine kinase signalling pathways have been successfully targeted to inhibit proliferation and angiogenesis for cancer therapy. However, kinase... 
CELL LUNG-CANCER | SELECTIVE-INHIBITION |